Communiqués Telix Pharmaceuticals Limited

Actions

TLX

AU000000TLX2

Recherche biotechnologique et médicale

Temps Différé Australian S.E. Autres places de cotation 06:59:06 05/08/2026			Varia. 5j.	Varia. 1 janv.
14,71 ^AUD	+2,08%		+1,31%	+31,16%

24/07	Telix : des données en vie réelle encourageantes pour son candidat contre le cancer de la thyroïde	MT
22/07	Telix Pharmaceuticals Limited publie les résultats de l'étude ProstACT SELECT évaluant le candidat thérapeutique TLX591-Tx	CI

Communiqués

24/07	EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer	PU
21/07	TLX591-Tx ProstACT SELECT Study Published in Cancers Journal	AQ
21/07	Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress	AQ
21/07	Telix Pharmaceuticals : Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress	PU
21/07	Telix Pharmaceuticals : Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress	PU
20/07	Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer	AQ
17/07	Telix Pharmaceuticals : Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study	PU
16/07	Telix Pharmaceuticals : Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing	PU
15/07	First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer	AQ
10/07	Telix Pharmaceuticals : Notification of cessation of securities - TLX	PU
02/07	FDA Alignment to Advance ProstACT Global Phase 3 Trial	GL
02/07	Telix Pharmaceuticals : FDA Alignment to Advance ProstACT Global Phase 3 Trial	PU
22/06	Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions	GL
22/06	Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions	PU
02/06	Telix and United Imaging Announce Strategic Theranostics Collaboration	AQ
01/06	ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026	AQ
01/06	Telix Pharmaceuticals : William Blair Growth Conference Presentation (7bff72)	PU
27/05	Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences	AQ
18/05	IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing	AQ
15/05	Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches	AQ
04/05	New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC	AQ
30/04	TLX101-Px (Pixlumi®) MAA Accepted in Europe	AQ
30/04	Unlocking the Potential of PSMA Therapy: A Next Generation Portfolio Approach (71df86)	PU
29/04	OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer	AQ
28/04	Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach	AQ